{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:02:40Z","timestamp":1792789360866,"version":"4.5.0"},"reference-count":130,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["22K11347"],"award-info":[{"award-number":["22K11347"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease, including end-stage kidney disease, and increases the risk of cardiovascular mortality. Although the treatment options for DKD, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, sodium-glucose cotransporter 2 inhibitors, and mineralocorticoid receptor antagonists, have advanced, their efficacy is still limited. Thus, a deeper understanding of the molecular mechanisms of DKD onset and progression is necessary for the development of new and innovative treatments for DKD. The complex pathogenesis of DKD includes various different pathways, and the mechanisms of DKD can be broadly classified into inflammatory, fibrotic, metabolic, and hemodynamic factors. Here, we summarize the recent findings in basic research, focusing on each factor and recent advances in the treatment of DKD. Collective evidence from basic and clinical research studies is helpful for understanding the definitive mechanisms of DKD and their regulatory systems. Further comprehensive exploration is warranted to advance our knowledge of the pathogenesis of DKD and establish novel treatments and preventive strategies.<\/jats:p>","DOI":"10.3390\/ijms24010570","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T02:56:50Z","timestamp":1672282610000},"page":"570","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["What\u2019s New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8773-0967","authenticated-orcid":false,"given":"Kimio","family":"Watanabe","sequence":"first","affiliation":[{"name":"Dialysis Center, Tohoku University Hospital, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-2745","authenticated-orcid":false,"given":"Eikan","family":"Mishima","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Rheumatology and Endocrinology, Graduate School of Medicine, Tohoku University, Sendai 980-8575, Japan"},{"name":"Institute of Metabolism and Cell Death, Helmholtz Zentrum M\u00fcnchen, 85764 Neuherberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Dialysis Center, Tohoku University Hospital, Sendai 980-8574, Japan"},{"name":"Division of Nephrology, Rheumatology and Endocrinology, Graduate School of Medicine, Tohoku University, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Rheumatology and Endocrinology, Graduate School of Medicine, Tohoku University, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic Kidney Disease: Challenges, Progress, and Possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.2215\/CJN.11111016","article-title":"Diagnosis and Management of Type 2 Diabetic Kidney Disease","volume":"12","author":"Doshi","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10741-014-9460-9","article-title":"Chronic kidney disease and cardiovascular complications","volume":"20","author":"House","year":"2015","journal-title":"Heart Fail. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease\u2014Mechanistic and therapeutic effects","volume":"18","author":"Bakris","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_5","first-page":"389","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease. Reply","volume":"384","author":"Heerspink","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ndt\/gfp599","article-title":"Bradykinin and high glucose promote renal tubular inflammation","volume":"25","author":"Tang","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41581-019-0234-4","article-title":"Innate immunity in diabetic kidney disease","volume":"16","author":"Tang","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11684-017-0569-9","article-title":"Non-genetic mechanisms of diabetic nephropathy","volume":"11","author":"Han","year":"2017","journal-title":"Front. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.kint.2016.12.006","article-title":"Circulating fibronectin contributes to mesangial expansion in a murine model of type 1 diabetes","volume":"91","author":"Klemis","year":"2017","journal-title":"Kidney Int."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Ahmad, A.A., Draves, S.O., and Rosca, M. (2021). Mitochondria in Diabetic Kidney Disease. Cells, 10.","DOI":"10.3390\/cells10112945"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1073\/pnas.120055097","article-title":"Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-\u03b2 antibody in db\/db diabetic mice","volume":"97","author":"Ziyadeh","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s13287-020-01852-y","article-title":"Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis","volume":"11","author":"Xiang","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molmet.2019.02.007","article-title":"Tim-3 aggravates podocyte injury in diabetic nephropathy by promoting macrophage activation via the NF-kappaB\/TNF-alpha pathway","volume":"23","author":"Yang","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/CMR.15.3.414-429.2002","article-title":"NF-kappaB family of transcription factors: Central regulators of innate and adaptive immune functions","volume":"15","author":"Caamano","year":"2002","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41591-019-0415-5","article-title":"A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes","volume":"25","author":"Niewczas","year":"2019","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.1002\/jcp.27427","article-title":"Interleukin-18 and diabetic nephropathy: A review","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41419-021-04184-8","article-title":"AMPK agonist alleviate renal tubulointerstitial fibrosis via activating mitophagy in high fat and streptozotocin induced diabetic mice","volume":"12","author":"Han","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4093\/dmj.2015.39.6.451","article-title":"Autophagy: A Novel Therapeutic Target for Diabetic Nephropathy","volume":"39","author":"Kume","year":"2015","journal-title":"Diabetes Metab. J."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Dusabimana, T., Park, E.J., Je, J., Jeong, K., Yun, S.P., Kim, H.J., Kim, H., and Park, S.W. (2021). Geniposide Improves Diabetic Nephropathy by Enhancing ULK1-Mediated Autophagy and Reducing Oxidative Stress through AMPK Activation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041651"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1172\/JCI121987","article-title":"PTEN-induced partial epithelial-mesenchymal transition drives diabetic kidney disease","volume":"129","author":"Li","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1038\/s41467-021-22617-y","article-title":"Loss of endothelial glucocorticoid receptor accelerates diabetic nephropathy","volume":"12","author":"Srivastava","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s13287-019-1401-z","article-title":"Intervention for early diabetic nephropathy by mesenchymal stem cells in a preclinical nonhuman primate model","volume":"10","author":"An","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.kint.2018.10.038","article-title":"Disulfide-bond A oxidoreductase-like protein protects against ectopic fat deposition and lipid-related kidney damage in diabetic nephropathy","volume":"95","author":"Chen","year":"2019","journal-title":"Kidney Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol. Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"107598","DOI":"10.1016\/j.intimp.2021.107598","article-title":"MCP-1: Function, regulation, and involvement in disease","volume":"101","author":"Singh","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.2337\/db18-1075","article-title":"LRNA9884, a Novel Smad3-Dependent Long Noncoding RNA, Promotes Diabetic Kidney Injury in db\/db Mice via Enhancing MCP-1-Dependent Renal Inflammation","volume":"68","author":"Zhang","year":"2019","journal-title":"Diabetes"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1681\/ASN.2019060582","article-title":"Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice","volume":"31","author":"Sugahara","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.kint.2019.12.007","article-title":"The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease","volume":"97","author":"Hasegawa","year":"2020","journal-title":"Kidney Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jdiacomp.2012.06.006","article-title":"Urinary MCP-1 and RBP: Independent predictors of renal outcome in macroalbuminuric diabetic nephropathy","volume":"26","author":"Tian","year":"2012","journal-title":"J. Diabetes Complicat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1681\/ASN.2020040487","article-title":"Association of Multiple Plasma Biomarker Concentrations with Progression of Prevalent Diabetic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study","volume":"32","author":"Schrauben","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"112260","DOI":"10.1016\/j.ejmech.2020.112260","article-title":"Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview","volume":"194","author":"Mondal","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Yang, H., Chen, H., Liu, F., and Ma, Q. (2021). Up-regulation of matrix metalloproteinases-9 in the kidneys of diabetic rats and the association with neutrophil gelatinase-associated lipocalin. BMC Nephrol., 22.","DOI":"10.1186\/s12882-021-02396-w"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13287-022-02857-5","article-title":"Intrarenal arterial administration of human umbilical cord-derived mesenchymal stem cells effectively preserved the residual renal function of diabetic kidney disease in rat","volume":"13","author":"Yue","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nm.3902","article-title":"Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis","volume":"21","author":"Lovisa","year":"2015","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/s41419-018-1157-x","article-title":"Renal tubular epithelial cells: The neglected mediator of tubulointerstitial fibrosis after injury","volume":"9","author":"Qi","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Wang, L., Wang, H.L., Liu, T.T., and Lan, H.Y. (2021). TGF-Beta as a Master Regulator of Diabetic Nephropathy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22157881"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1080\/15548627.2020.1824694","article-title":"SMAD3 promotes autophagy dysregulation by triggering lysosome depletion in tubular epithelial cells in diabetic nephropathy","volume":"17","author":"Yang","year":"2021","journal-title":"Autophagy"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1681\/ASN.2018060599","article-title":"LRG1 Promotes Diabetic Kidney Disease Progression by Enhancing TGF-beta-Induced Angiogenesis","volume":"30","author":"Hong","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.kint.2021.10.023","article-title":"Modulation of transforming growth factor-beta-induced kidney fibrosis by leucine-rich-2 glycoprotein-1","volume":"101","author":"Hong","year":"2022","journal-title":"Kidney Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13287-020-02108-5","article-title":"Administration of mesenchymal stem cells in diabetic kidney disease: A systematic review and meta-analysis","volume":"12","author":"Lin","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"C340","DOI":"10.1152\/ajpcell.00167.2018","article-title":"Early growth response protein-1 upregulates long noncoding RNA Arid2-IR to promote extracellular matrix production in diabetic kidney disease","volume":"316","author":"Yang","year":"2019","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s41232-018-0070-0","article-title":"CTGF in kidney fibrosis and glomerulonephritis","volume":"38","author":"Toda","year":"2018","journal-title":"Inflamm. Regen."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1053\/j.ajkd.2021.08.009","article-title":"Serum Level of Polyubiquitinated PTEN and Loss of Kidney Function in American Indians With Type 2 Diabetes","volume":"79","author":"Looker","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.2337\/db20-0579","article-title":"YAP Activation in Renal Proximal Tubule Cells Drives Diabetic Renal Interstitial Fibrogenesis","volume":"69","author":"Chen","year":"2020","journal-title":"Diabetes"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1002\/jcp.25867","article-title":"Palmitate induces mitochondrial superoxide generation and activates AMPK in podocytes","volume":"232","author":"Lee","year":"2017","journal-title":"J. Cell. Physiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2337\/diabetes.55.01.06.db05-0894","article-title":"Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy","volume":"55","author":"Susztak","year":"2006","journal-title":"Diabetes"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nri2725","article-title":"NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production?","volume":"10","author":"Tschopp","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ki.2014.271","article-title":"Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy","volume":"87","author":"Shahzad","year":"2015","journal-title":"Kidney Int."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"16485","DOI":"10.1002\/jcp.28317","article-title":"Thioredoxin-interacting protein deficiency alleviates phenotypic alterations of podocytes via inhibition of mTOR activation in diabetic nephropathy","volume":"234","author":"Song","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"154748","DOI":"10.1016\/j.metabol.2021.154748","article-title":"Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy","volume":"118","author":"Wu","year":"2021","journal-title":"Metabolism"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41419-021-03813-6","article-title":"CD36 promotes NLRP3 inflammasome activation via the mtROS pathway in renal tubular epithelial cells of diabetic kidneys","volume":"12","author":"Hou","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrneph.2017.126","article-title":"CD36 in chronic kidney disease: Novel insights and therapeutic opportunities","volume":"13","author":"Yang","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"100968","DOI":"10.1016\/j.molmet.2020.02.011","article-title":"Interplay between RNA-binding protein HuR and Nox4 as a novel therapeutic target in diabetic kidney disease","volume":"36","author":"Shi","year":"2020","journal-title":"Mol. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.2337\/db21-1079","article-title":"Independent of Renox, NOX5 Promotes Renal Inflammation and Fibrosis in Diabetes by Activating ROS-Sensitive Pathways","volume":"71","author":"Jha","year":"2022","journal-title":"Diabetes"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1681\/ASN.V1191656","article-title":"Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease","volume":"11","author":"Tanji","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.freeradbiomed.2021.05.025","article-title":"AGE\/RAGE in diabetic kidney disease and ageing kidney","volume":"171","author":"Wu","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"960","DOI":"10.2337\/db17-0538","article-title":"RAGE Deletion Confers Renoprotection by Reducing Responsiveness to Transforming Growth Factor-beta and Increasing Resistance to Apoptosis","volume":"67","author":"Hagiwara","year":"2018","journal-title":"Diabetes"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1159\/000486154","article-title":"Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling","volume":"44","author":"Hou","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.2337\/db11-1546","article-title":"Alagebrium Reduces Glomerular Fibrogenesis and Inflammation Beyond Preventing RAGE Activation in Diabetic Apolipoprotein E Knockout Mice","volume":"61","author":"Watson","year":"2012","journal-title":"Diabetes"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2337\/db16-1281","article-title":"RAGE-Aptamer Blocks the Development and Progression of Experimental Diabetic Nephropathy","volume":"66","author":"Matsui","year":"2017","journal-title":"Diabetes"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.2337\/db20-1257","article-title":"Vaccination Against Receptor for Advanced Glycation End Products Attenuates the Progression of Diabetic Kidney Disease","volume":"70","author":"Azegami","year":"2021","journal-title":"Diabetes"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1159\/000108104","article-title":"Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy","volume":"27","author":"Williams","year":"2007","journal-title":"Am. J. Nephrol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s00125-008-1224-4","article-title":"High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: A randomised, double-blind placebo-controlled pilot study","volume":"52","author":"Rabbani","year":"2009","journal-title":"Diabetologia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000075627","article-title":"Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy","volume":"24","author":"Bolton","year":"2004","journal-title":"Am. J. Nephrol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.2337\/dc09-2241","article-title":"A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy","volume":"33","author":"Alkhalaf","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4093\/dmj.2020.0217","article-title":"Treatment of Diabetic Kidney Disease: Current and Future","volume":"45","author":"Yamazaki","year":"2021","journal-title":"Diabetes Metab. J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"11704","DOI":"10.1073\/pnas.91.24.11704","article-title":"Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats","volume":"91","author":"Vlassara","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1017\/S0954422420000104","article-title":"The potential role of dietary advanced glycation endproducts in the development of chronic non-infectious diseases: A narrative review","volume":"33","author":"Beeri","year":"2020","journal-title":"Nutr. Res. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"eabe4841","DOI":"10.1126\/sciadv.abe4841","article-title":"Processed foods drive intestinal barrier permeability and microvascular diseases","volume":"7","author":"Snelson","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1681\/ASN.2013080905","article-title":"The Gut Microbiome, Kidney Disease, and Targeted Interventions","volume":"25","author":"Ramezani","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Ma, J., Chadban, S.J., Zhao, C.Y., Chen, X.C., Kwan, T., Panchapakesan, U., Pollock, C.A., and Wu, H.L. (2014). TLR4 Activation Promotes Podocyte Injury and Interstitial Fibrosis in Diabetic Nephropathy. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0097985"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41467-019-09735-4","article-title":"Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease","volume":"10","author":"Kikuchi","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1681\/ASN.2021060843","article-title":"Intestinal Bacterial Translocation Contributes to Diabetic Kidney Disease","volume":"33","author":"Linh","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1681\/ASN.2019101029","article-title":"Dietary Fiber Protects against Diabetic Nephropathy through Short-Chain Fatty Acid?Mediated Activation of G Protein? Coupled Receptors GPR43 and GPR109A","volume":"31","author":"Li","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.diabet.2014.10.003","article-title":"The impact of hyperfiltration on the diabetic kidney","volume":"41","author":"Premaratne","year":"2015","journal-title":"Diabetes Metab."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41581-018-0001-y","article-title":"CKD in diabetes: Diabetic kidney disease versus nondiabetic kidney disease","volume":"14","author":"Anders","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","article-title":"The tubular hypothesis of nephron filtration and diabetic kidney disease","volume":"16","author":"Vallon","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dbi16-0056","article-title":"Back to the Future: Glomerular Hyperfiltration and the Diabetic Kidney","volume":"66","author":"Tuttle","year":"2017","journal-title":"Diabetes"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.cmet.2022.05.010","article-title":"Mapping the single-cell transcriptomic response of murine diabetic kidney disease to therapies","volume":"34","author":"Wu","year":"2022","journal-title":"Cell Metab."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: Impact of SGLT2 inhibitors","volume":"17","author":"DeFronzo","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/jcp.30621","article-title":"Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease","volume":"237","author":"Ravindran","year":"2022","journal-title":"J. Cell. Physiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cmet.2020.06.020","article-title":"SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition","volume":"32","author":"Tomita","year":"2020","journal-title":"Cell Metab."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"107954","DOI":"10.1016\/j.celrep.2020.107954","article-title":"Proximal Tubule mTORC1 Is a Central Player in the Pathophysiology of Diabetic Nephropathy and Its Correction by SGLT2 Inhibitors","volume":"32","author":"Hinden","year":"2020","journal-title":"Cell Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.2337\/db17-1323","article-title":"Inflammation and Immunity Pathways Regulate Genetic Susceptibility to Diabetic Nephropathy","volume":"67","author":"Gurley","year":"2018","journal-title":"Diabetes"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"F1183","DOI":"10.1152\/ajprenal.00159.2003","article-title":"A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli","volume":"288","author":"Singh","year":"2005","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/HYPERTENSIONAHA.107.102467","article-title":"Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment","volume":"51","author":"Habibi","year":"2008","journal-title":"Hypertension"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1681\/ASN.2018030280","article-title":"A NOX4\/TRPC6 Pathway in Podocyte Calcium Regulation and Renal Damage in Diabetic Kidney Disease","volume":"29","author":"Ilatovskaya","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.kint.2022.01.031","article-title":"Deficiency of the kidney tubular angiotensin II type1 receptor-associated protein ATRAP exacerbates streptozotocin-induced diabetic glomerular injury via reducing protective macrophage polarization","volume":"101","author":"Haruhara","year":"2022","journal-title":"Kidney Int."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jfma.2018.02.007","article-title":"Update of pathophysiology and management of diabetic kidney disease","volume":"117","author":"Lin","year":"2018","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1093\/ndt\/gfp206","article-title":"Aldosterone, a vasculotoxic agent--novel functions for an old hormone","volume":"24","author":"Ritz","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.semnephrol.2015.02.004","article-title":"Endothelin and the renal microcirculation","volume":"35","author":"Guan","year":"2015","journal-title":"Semin. Nephrol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1210\/endrev\/bnz010","article-title":"The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications","volume":"41","author":"Lytvyn","year":"2020","journal-title":"Endocr. Rev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.2337\/db15-1413","article-title":"Atrasentan Reduces Albuminuria by Restoring the Glomerular Endothelial Glycocalyx Barrier in Diabetic Nephropathy","volume":"65","author":"Boels","year":"2016","journal-title":"Diabetes"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"553","DOI":"10.4239\/wjd.v11.i11.553","article-title":"Endothelin receptor antagonists for the treatment of diabetic nephropathy: A meta-analysis and systematic review","volume":"11","author":"Zhang","year":"2020","journal-title":"World J. Diabetes"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2337\/dbi18-0007","article-title":"Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease","volume":"68","author":"Alicic","year":"2019","journal-title":"Diabetes"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00125-021-05512-5","article-title":"Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial","volume":"64","author":"Sen","year":"2021","journal-title":"Diabetologia"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1007\/s00125-018-4678-z","article-title":"SGLT2 inhibitors: The future for treatment of type 2 diabetes mellitus and other chronic diseases","volume":"61","author":"Wanner","year":"2018","journal-title":"Diabetologia"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2020). 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2020. Diabetes Care., 43, S135\u2013S151.","DOI":"10.2337\/dc20-S011"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ahj.2020.10.064","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials","volume":"232","author":"Salah","year":"2021","journal-title":"Am. Heart J."},{"key":"ref_112","unstructured":"Group, E.-K.C., Herrington, W.G., Staplin, N., Wanner, C., Green, J.B., Hauske, S.J., Emberson, J.R., Preiss, D., Judge, P., and Mayne, K.J. (2022). Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ajh\/hpaa137","article-title":"Aldosterone, Inflammation, Immune System, and Hypertension","volume":"34","author":"Ferreira","year":"2021","journal-title":"Am. J. Hypertens."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"Khunti","year":"2022","journal-title":"Kidney Int."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","article-title":"Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: An update based on rapidly emerging new evidence","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jchf.2020.11.009","article-title":"Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF","volume":"9","author":"Shen","year":"2021","journal-title":"JACC Heart Fail."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","article-title":"Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced","volume":"77","author":"Ferreira","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: Biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2337\/dc21-1113","article-title":"Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes","volume":"45","author":"Wright","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): A double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/ki.2012.439","article-title":"Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease","volume":"83","author":"Ruiz","year":"2013","journal-title":"Kidney Int."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ekir.2020.03.030","article-title":"Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study)","volume":"5","author":"Nangaku","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Nangaku, M., Takama, H., Ichikawa, T., Mukai, K., Kojima, M., Suzuki, Y., Watada, H., Wada, T., Ueki, K., and Narita, I. (2022). Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: Design and baseline characteristics of AYAME study. Nephrol. Dial. Transplant., gfac242.","DOI":"10.1093\/ndt\/gfac242"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1681\/ASN.2018121231","article-title":"Effects of Selonsertib in Patients with Diabetic Kidney Disease","volume":"30","author":"Chertow","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_129","unstructured":"Gilead Sciences (2022, November 15). Study Evaluating the Efficacy and Safety of Selonsertib in Participants with Moderate to Advanced Diabetic Kidney Disease (MOSAIC), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04026165."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Rayego-Mateos, S., Rodrigues-Diez, R., Fernandez-Fernandez, B., Mora-Fernandez, C., Marchant, V., Donate-Correa, J., Navarro-Gonzalez, J.F., Ortiz, A., and Ruiz-Ortega, M. (2022). Targeting inflammation to treat diabetic kidney disease: The road to 2030. Kidney Int.","DOI":"10.1016\/j.kint.2022.10.030"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/1\/570\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:54:57Z","timestamp":1760147697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/1\/570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":130,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ijms24010570"],"URL":"https:\/\/doi.org\/10.3390\/ijms24010570","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]}}}